Ypsomed generated CHF 286.6 million in revenue from injection systems for self-administered medications in the first half of fiscal 2026/27, up 17.5 percent from the same period a year earlier. According to its November 11, 2026 ad hoc announcement, the segment’s operating profit (EBIT) rose 16.8 percent to CHF 102.3 million. The EBIT margin was 35.7...
Read more on plasticker.de